Silence Therapeutics PLC Sponsored ADR

SLN Healthcare Biotechnology

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.

8.68 0.67 −7.17%
Market cap
$581.1M
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
2/9
Altman Z
−4.82
Beneish M
45.78
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 1 3 —
ROE
(65.53%) (90.27%) (236.94%) (90.41%)
ROA
(35.16%) (53.05%) (49.96%) (44.14%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(54.74%) (83.11%) (80.01%) (72.33%)
Average Days of Receivables
313.42 14,369.51 9,664.89 0.00
Free Cash Flow per Share
(1.54) (1.32) (1.39) (0.89)
Free Cash Flow
(72.58) (62.33) (65.56) (42.26)
Capital Expenditures
(0.12) (0.05) — —
Other line items
Cash ROIC
(41.18%) (42.26%) (54.86%) (38.24%)
Accounts Receivable Turnover
1.18 0.02 0.04 0.00
Accounts Payable Turnover
0.13 0.01 0.01 0.00
Inventory Turnover
0.00 0.00 0.00 —
Average Days of Payables
2,767.71 22,674.14 21,999.74 0.00
Days of Inventory on Hand
0.00 0.00 0.00 —
Tax Rate
0.01 0.00 0.00 0.01
Research and Development Expense of Revenue
313.90% 12,120.39% 6,682.00% 0.00%
Selling, General and Administrative Expense of Revenue
93.51% 3,997.14% 2,584.74% 0.00%
Share Based Compensation of Revenue
47.00% 1,444.36% 832.06% 0.00%
Operating CF/Net income
1.12 0.70 0.87 0.70
Depreciation/Fixed assets
0.35 0.35 0.37 0.36
Capex/Depreciation
(0.20) (0.10) 0.00 0.00
Revenue per Share
0.55 0.01 0.02 0.00
Operating CF per Share
(1.53) (1.32) (1.39) (0.89)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.10 0.00 —

Fold the line items

Columns are period end dates